Biohaven’s multimodal antibody therapy demonstrated effective neutralization of multiple strains of COVID-19
On Feb. 22, 2021, Biohaven Pharmaceutical announced that a hyperimmune globulin mimic (HGM) developed with Biohaven’s proprietary MATE…
On Feb. 22, 2021, Biohaven Pharmaceutical announced that a hyperimmune globulin mimic (HGM) developed with Biohaven’s proprietary MATE…
On Feb. 22, 2021, Novavax and the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the…
On Feb. 19, 2021, the ACT Accelerator partnership welcomed over US$ 4.3 billion of new investments from the…
On Feb. 19, 2021, Johnson & Johnson announced that Janssen-Cilag had submitted for Emergency Use Listing (EUL) to…
On Feb. 19, 2021, BioNTech announced the submission of new data to the FDA demonstrating the stability of…
On Feb. 18, 2021, scientists at the University of Oxford announced that the Randomised Evaluation of COVID-19 Therapy…
On Feb. 18, 2021, Novavax and announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to…
On Feb. 18, 2021, Washington University pediatric infectious diseases doctors announced plans to launch clinical trials in the…
On Feb. 18, 2021, Pfizer and BioNTech announced that the first participants hadbeen dosed in a global Phase…
On Feb. 17, 2021, the NIH annunced funding of a study to evaluate the effects of remdesivir in…
On Feb. 17, 2021, Moderna announced that the European Commission had purchased an additional 150 million doses of…
On Feb. 17, 2021, Altimmune announced that the FDA had cleared the Companyï¾’s Investigational New Drug (IND) application…
On Feb. 17, 2021, LabCorp announced the availability of a new laboratory-based antigen test that will help doctors…
On Feb. 17, 2021, BioNTech announced an agreement with the European Commission (EC) to supply an additional 200…
On Feb. 17, 2021, Immunic announced that its lead asset, IMU-838, the company’s selective oral DHODH inhibitor, had…
On Feb. 17, 2021, BioNTech announced results from an in vitro study that provided additional data on the…
On Feb. 16, 2021, XPhyto and 3a-diagnostics announced that all actions and procedures required for its European regulatory…
On Feb. 16, 2021, AIM ImmunoTech announced that it had received approval from the required Ethics Committee in…
On Feb. 16, 2021, Moderna provided a supply update for their COVID-19 Vaccine in the United States, reporting…
On Feb. 16, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, has submitted a conditional Marketing Authorisation…
On Feb. 15, 2021, the WHO listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use, giving…
On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to…
On Feb. 12, 2021, CureVac announced initiation of a rolling submission with the European Medicines Agency (EMA) for…
On Feb. 12, 2021, the NIH announced that enrollment had begun to test additional investigational drugs in the…
On Feb. 12, 2021, Moderna announced that the Canadian Government had increased its confirmed order commitment by 4…
On Feb. 12, 2021, BD (Becton, Dickinson) announced that the FDA had granted Emergency Use Authorization (EUA) for…
On Feb. 12, 2021, BioNTech announced that the U.S. government had exercised its option for an additional 100…
On Feb. 11, 2021, the WHO announced that COVID-19 cases and deaths surged in Africa as more contagious…
On Feb. 11, 2021, ImmunityBio and NantKwest announced they had received FDA authorization to expand Phase I testing…
On Feb. 11, 2021, Cue Health announced the results of an independent clinical validation study conducted by Mayo…